Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.

June 23rd 2025. Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the ...

Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related ...

May 5th 2025. The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

In a comprehensive study of geographic atrophy (GA) treatment, Deepak Sambhara, MD, from the Eye Clinic of Wisconsin analyzed long-term patient compliance with two recently FDA-approved complement ...

EyePoint Pharmaceuticals recently announced the enrollment and randomization of its phase 3 LUGANO trial (NCT06668064) of DURAVYU for the treatment of wet age-related macular degeneration (wet ...

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Alkeus Pharmaceuticals, Inc., announced additional data from its Phase 2 clinical SAGA study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).In this trial patients ...